Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 8,664 shares at $330.56 ($2.5M) on 2019-11-08, disclosed to the SEC on 2019-11-12.
Open-market sale of $2.5M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,300 | $0 | 0.0% |
| 2 | $330.56 | 100 | $33K | 1.3% |
| 3 | $333.32 | 200 | $67K | 2.7% |
| 4 | $334.66 | 100 | $33K | 1.3% |
| 5 | $335.45 | 400 | $134K | 5.4% |
| 6 | $336.73 | 500 |
| $168K |
| 6.8% |
| 7 | $337.41 | 1,500 | $506K | 20.3% |
| 8 | $338.54 | 1,100 | $372K | 14.9% |
| 9 | $339.53 | 1,100 | $373K | 15.0% |
| 10 | $340.48 | 2,064 | $703K | 28.2% |
| 11 | $341.38 | 300 | $102K | 4.1% |
| Total | $287.73 avg | 8,664 | $2.5M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |